Bill > HB3799

This bill creates a legal framework for patients with terminal or severe chronic diseases to receive experimental medical treatments not yet approved by the FDA. The bill defines key terms such as "investigational product" as a drug or device still under clinical investigation and not yet FDA-approved, and establishes detailed requirements for how such treatments can be offered. To qualify, patients must be Oregon residents, at least 18 years old, and capable of making informed medical decisions. The bill requires multiple physician consultations, including an attending physician who must inform the patient about risks, potential ineffectiveness, and alternative treatments like palliative care. Patients must sign a liability waiver and acknowledge that their health insurance will not cover the experimental treatment. Healthcare practitioners offering these treatments are protected from civil or criminal liability as long as they follow the prescribed procedures, though gross negligence is not protected. The bill also mandates that the Oregon Health Authority annually review records of these treatments and generate statistical reports, ensuring some oversight while maintaining patient privacy. Importantly, the bill aims to provide terminally ill patients with additional treatment options while establishing clear legal protections for both patients and healthcare providers.

Health and Social Services

https://olis.oregonlegislature.gov/liz/2025R1/Measures/Overview/HB3799